Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

mantle cell lymphoma

Aliases
Mantle Cell Lymphoma

149 clinical trials

144 products

19 drugs

Product
Pirtobrutinib
Product
Venetoclax
Product
Rituximab
Clinical trial
A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2027-09-01
Product
STK-009
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-06-24
Clinical trial
A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of Loncastuximab Tesirine and Ibrutinib in Patients With Advanced Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma (LOTIS-3)
Status: Terminated, Estimated PCD: 2022-11-08
Product
Loncastuximab Tesirine
Product
Cyclophosphamide
Product
Ibrutinib
Product
SYNCAR-001
Product
Fludarabine
Clinical trial
A Phase Ib, Multi-center, Open-label Dose Escalation and Expansion Platform Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma (NHL)
Status: Recruiting, Estimated PCD: 2026-10-30
Product
VAY736
Product
lenalidomide
Product
pembrolizumab
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Product
Chemotherapy
Clinical trial
A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas
Status: Recruiting, Estimated PCD: 2026-04-30
Product
ONM-501
Product
Cemiplimab
Product
CDX-1140
Product
CDX-301
Product
Orelabrutinib
Clinical trial
A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study of Orelabrutinib in Combination With Rituximab and Bendamustine (BR) vs. BR in Subjects With Treatment-Naїve Mantle Cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2034-12-25
Product
ATA3219
Clinical trial
A Phase 1 Study to Evaluate the Safety and Preliminary Efficacy of ATA3219, Allogeneic Anti-CD19 Chimeric Antigen Receptor T-cell Therapy, in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2026-05-01
Product
L-Bcl-2 antisense oligonucleotide
Clinical trial
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
Status: Recruiting, Estimated PCD: 2024-09-01
Product
Bendamustine
Product
Nemtabrutinib
Clinical trial
A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS-101 in Subjects With Hematological Malignancies (waveLINE-001)
Status: Completed, Estimated PCD: 2023-12-18
Product
Zilovertamab
Product
BGB-10188
Product
Zanubrutinib
Product
Tislelizumab
Clinical trial
Safety of 131I-omburtamab Delivered by Convection-Enhanced Delivery in Patients With Diffuse Intrinsic Pontine Glioma Previously Treated With External Beam Radiation Therapy
Status: Withdrawn, Estimated PCD: 2026-03-01
Clinical trial
A Phase 1/2, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kδ) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-02-13
Clinical trial
An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or Refractory (R/R) Select B-Cell Malignancies (CLOVER-1) and Expansion Cohort in Patients With Waldenstrom Macroglobulinemia (CLOVER-WaM)
Status: Recruiting, Estimated PCD: 2024-11-30
Product
Iopofosine I 131
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase Targeted Protein Degrader BGB-16673 in Patients With B-Cell Malignancies
Status: Recruiting, Estimated PCD: 2024-09-30
Product
AS-1763
Clinical trial
A Phase 1b Study of Oral AS-1763 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2027-09-01
Product
BGB-16673
Product
NKX019
Clinical trial
A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Subjects With Mature B-Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1b Multi-cohort Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TG-1801
Product
Ublituximab
Product
SGR-1505
Product
L-Bcl-2
Product
P-CD19CD20-ALLO1
Clinical trial
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies
Status: Recruiting, Estimated PCD: 2029-03-01
Product
Rimiducid
Clinical trial
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
Status: Recruiting, Estimated PCD: 2027-03-13
Product
PRT1419
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies
Status: Terminated, Estimated PCD: 2024-01-19
Product
Azacitidine
Clinical trial
A Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN301，An Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-cell Non-Hodgkin's Lymphoma
Status: Terminated, Estimated PCD: 2023-12-25
Product
BN301
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation and Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Chinese Patients With B-Cell Malignancies
Status: Recruiting, Estimated PCD: 2027-03-01
Product
Brexucabtagene Autoleucel
Clinical trial
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Status:
Clinical trial
An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-10-31
Product
Fluconazole
Product
Repaglinide
Product
CYT-0851
Clinical trial
A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-07-30
Clinical trial
A Randomized,Open-label, Multicenter, Phase II Trial Evaluating Two Different Doses of Orelabrutinib in Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-02-25
Clinical trial
Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Status: Completed, Estimated PCD: 2022-12-02
Clinical trial
A Multi-center Phase II Study With Safety Run-in Evaluating the Efficacy and Safety of Ublituximab in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Status: Completed, Estimated PCD: 2015-12-01
Product
ICP-022
Product
TC-110
Product
STRO-001
Clinical trial
Safety and Efficacy of GEN3009 (DuoHexaBody®-CD37) in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A First-in-Human, Open-label, Phase 1/2a Dose Escalation Trial With Dose Expansion Cohorts
Status: Terminated, Estimated PCD: 2022-11-21
Clinical trial
A Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2023-01-01
Product
Elimusertib
Clinical trial
A Phase Ib Study of BTK Inhibitor DTRMWXHS-12 in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Status: Completed, Estimated PCD: 2021-11-17
Product
GEN3009
Product
Epcoritamab
Product
DTRMWXHS-12
Product
Tazemetostat
Product
Omeprazole
Clinical trial
A Randomized, Two-period, Two-sequence Two-treatment Crossover Design Food Effect Study to Evaluate the Pharmacokinetic Profile of LP-168 Tablets in Healthy Subjects After Single Oral Administration Under Fasted and Fed Conditions
Status: Completed, Estimated PCD: 2023-08-21
Clinical trial
A Multicenter, Open-label, Phase 1 Study Evaluating the Safety and Tolerability of HMPL-760 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Other Non-Hodgkin Lymphoma (NHL)
Status: Withdrawn, Estimated PCD: 2022-11-16
Product
HMPL-760
Clinical trial
A Phase 1b, Open-Label, Multicenter Study of FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Status: Withdrawn, Estimated PCD: 2026-05-01
Product
FT596
Product
Doxorubicin
Product
LP-168
Product
Vincristine
Product
Prednisone
Product
NVG-111
Clinical trial
An Open-label, Phase 1, First in Human Study Investigating the Safety, Tolerability, Pharmacokinetics and Efficacy of NVG-111 in Subjects With Relapsed/Refractory ROR1+ Malignancies
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase I, Multicenter, Open-Label, Dose-escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Orally Administered LP-168 in Subjects With Relapsed or Refractory B-cell Malignancies.
Status: Recruiting, Estimated PCD: 2025-07-31
Product
CTX112
Product
APR-246
Product
APR-246 + Venetoclax + Rituximab
Clinical trial
Phase 1 and Dose Expansion Study of APR-246 in Combination With Acalabrutinib or Venetoclax-based Therapy in Subjects With R/R NHL Including Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)
Status: Terminated, Estimated PCD: 2021-08-23
Product
IKS03
Clinical trial
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas (NHL)
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Phase II Open-Label, Single-Arm, Multicenter Study of JWCAR029, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-10-25
Clinical trial
A Phase 1/2, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies
Status: Recruiting, Estimated PCD: 2030-01-01
Product
CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
Product
Abemaciclib
Clinical trial
Phase 2 Study of a CDK4/6 Inhibitor for Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2015-09-28
Clinical trial
A Phase Ib/II Clinical Trial of TQB3909 Tablets in Subjects With Relapsed or Refractory MCL Safety and Efficacy
Status: Recruiting, Estimated PCD: 2024-12-01
Product
TQB3909
Clinical trial
A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Pharmacokinetics of Imvotamab (IGM-2323) as a Single Agent and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas
Status: Active (not recruiting), Estimated PCD: 2024-10-01
Product
Cirmtuzumab
Clinical trial
A Phase 1b/2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
imvotamab
Product
Cirmtuzumab plus ibrutinib
Clinical trial
Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Status: Recruiting, Estimated PCD: 2028-03-22
Product
CAR.k.28
Drug
fludarabine
Clinical trial
A Phase II Study of Rituximab/Bendamustine Followed by Rituximab/Cytarabine for Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2015-02-01
Drug
Varlilumab
Product
Cytarabine
Clinical trial
Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2019-12-01
Clinical trial
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Pembrolizumab
Clinical trial
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance
Status: Active (not recruiting), Estimated PCD: 2019-03-01
Product
Obinutuzumab
Product
Dexamethasone
Product
Aracytine
Drug
Cisplatin
Product
Etoposide
Drug
Melphalan
Product
Carmustine
Clinical trial
A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas
Status: Recruiting, Estimated PCD: 2026-09-01
Product
IBRUTINIB
Clinical trial
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-11-01
Product
BGB-11417
Clinical trial
Phase II Trial of Ibrutinib in Perviously Untreated High Risk Smoldering Mantle Cell Lymphoma (MCL)
Status: Active (not recruiting), Estimated PCD: 2026-02-28
Clinical trial
A Phase II Study of Acalabrutinib in Combination With R-CHOP Chemotherapy in Previously Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-09-30
Product
Acalabrutinib
Product
R-CHOP
Clinical trial
Zanubrutinib Plus Rituximab (Zanu -R) as Fixed Duration, Early Intervention Versus Observation for Patients With Indolent Mantle Cell Lymphoma: a Randomised Phase II Clinical Trial
Status: Recruiting, Estimated PCD: 2028-10-01
Drug
Zanubrutinib
Clinical trial
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Status: Completed, Estimated PCD: 2023-11-07
Product
Lenalidomide
Drug
R-CHOP
Drug
cyclophosphamide
Clinical trial
CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-08-01
Product
CLIC-2201
Clinical trial
A Phase 1, Open-label, Dose Escalating Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the Combination of CLBR001 and SWI019 in Patients With Relapsed/Refractory B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-04-01
Product
CLBR001
Clinical trial
A Phase I Study of Bivalent CD79b and CD19 Directed CAR T Cells in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2027-01-01
Product
CD79b-19 CAR T cells
Clinical trial
A Phase 1/2 Multi-Center Trial of Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation
Status: Recruiting, Estimated PCD: 2025-06-30
Product
Vorinostat
Clinical trial
A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2026-01-01
Product
PRGN-3007
Clinical trial
A Phase 2 Study of Glofitamab With Acalabrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-09-30
Product
Glofitamab
Clinical trial
A Pilot Study of Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2019-01-16
Product
Pegfilgrastim
Drug
Filgrastim
Product
Tacrolimus
Product
Methotrexate
Product
Mycophenolate Mofetil
Clinical trial
Phase 2 Study of Tafasitamab and Lenalidomide in Relapsed or Refractory Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-03-14
Drug
Tafasitamab
Clinical trial
Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Status: Active (not recruiting), Estimated PCD: 2017-01-03
Product
High-dose Cytarabine
Clinical trial
A Feasibility Study Following a Phase 2a Design to Demonstrate Successful Local Manufacture of Chimeric Antigen Receptor (CAR) T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2037-08-05
Product
Chimeric Antigen Receptor (CAR) T-Cell Product
Clinical trial
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutnib Combined With R-CHOP/R-DHAP Alternating Regimen for First-line MCL and Followed by Zanubrutinib Rituximab Maintenance Therapy
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Clinical trial
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Status: Active (not recruiting), Estimated PCD: 2024-10-09
Product
Anti-OX40 Antibody BMS 986178
Product
SD-101
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) in Subjects With Newly Diagnosed Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-06-01
Product
Placebo
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
Status: Active (not recruiting), Estimated PCD: 2024-07-31
Clinical trial
A Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Status: , Estimated PCD: 2025-03-01
Clinical trial
Multicenter Phase II Study of Ixazomib Maintenance in Patients With Newly Diagnosed Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-05-31
Product
Ixazomib
Clinical trial
Phase I/II Study of RAD001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia in Blastic-Phase, Agnogenic Myeloid Metaplasia, Chronic Lymphocytic Leukemia, T-Cell Leukemia, or Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2006-09-01
Product
RAD001
Clinical trial
Bendamustine + Obinutuzumab Induction Chemoimmunotherapy With Risk-adapted Obinutuzumab Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma
Status: Terminated, Estimated PCD: 2023-07-31
Clinical trial
A Phase II Study of Modified VR-CAP and Acalabrutinib as First Line Therapy for Transplant-Eligible Patients With Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-08-03
Product
Bortezomib
Product
Rituximab + Hyaluronidase Human
Clinical trial
Phase 1/2 Study of the Combination of Glofitamab, Venetoclax and Lenalidomide in Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-02-01
Clinical trial
Phase I Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2024-01-22
Product
BR-I
Clinical trial
IIT2022-04-Sasine-CAR-T: A Phase 1 Single-arm, Open-label Study to Evaluate the Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Status: Recruiting, Estimated PCD: 2025-12-15
Product
Autologous Hematopoietic Stem Cells
Clinical trial
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Status: Recruiting, Estimated PCD: 2027-04-28
Clinical trial
Efficacy of Alternating Immunochemotherapy Consisting of R-CHOP + R-HAD vs R-CHOP Alone, Followed by Maintenance Therapy Consisting of Additional Lenalidomide + Rituximab vs Rituximab Alone for Older Patients With Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2020-11-30
Product
R-CHOP / R-HAD
Clinical trial
A Single-arm, Open-label, National Multi-center Clinical Study of Linperlisib in Combination With Obinutuzumab and Venetoclax in the Treatment of Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma (R/R BV-MCL)
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Product
Linperlisib + Obinutuzumab + Venetoclax
Clinical trial
A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
Single Arm, Phase II Study of Acalabrutinib as Post-Autologous Blood or Marrow Transplant (BMT) Maintenance Therapy in Subjects With Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2024-04-05
Clinical trial
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With Ibrutinib and Local Radiation in Relapsed or Refractory Low-Grade Follicular Lymphoma
Status: Completed, Estimated PCD: 2023-05-18
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: A Window Period for Bioimmunotherapy Before Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
anti-CD19 CAR-T cells
Clinical trial
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Status: Recruiting, Estimated PCD: 2024-10-22
Product
Inactivated Influenza Vaccine
Clinical trial
A Phase II Study of Ibrutinib Plus Rituximab Followed by Venetoclax and Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma: Window II Protocol
Status: Active (not recruiting), Estimated PCD: 2025-05-22
Drug
Vincristine
Clinical trial
A Phase II Evaluation of Bendamustine, Obinutuzumab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-09-06
Clinical trial
A Randomized Phase II Study to Compare the Net Clinical Benefit of Cyclosporine and Sirolimus Combined With MMF or Post-Transplant Cyclophosphamide as GVHD Prophylaxis After HLA-Matched or HLA-Mismatched Unrelated G-CSF Mobilized Blood Cell Transplantation Using Nonmyeloablative or Reduced Intensity Conditioning for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-10-11
Product
Cyclosporine
Clinical trial
A Phase II Study of Palbociclib (PD-0332991) in Combination With Ibrutinib in Patients With Previously Treated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-06-30
Product
Palbociclib
Clinical trial
Phase II Study of Lenalidomide Plus Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2014-04-01
Drug
lenalidomide
Drug
rituximab
Clinical trial
Phase Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Lymphomas
Status: Recruiting, Estimated PCD: 2031-04-01
Product
CD22CART
Clinical trial
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-03-31
Clinical trial
A Window Study of Ixazomib in Untreated Indolent B-NHL
Status: Active (not recruiting), Estimated PCD: 2025-01-06
Clinical trial
Phase Ib/II Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL)
Status: Terminated, Estimated PCD: 2022-06-30
Product
Umbralisib
Clinical trial
Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)
Status: Active (not recruiting), Estimated PCD: 2024-06-30
Clinical trial
Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2027-01-01
Product
Acalabrutinib-rituximab
Clinical trial
Safety and Tolerability of Myeloablative Conditioning and Autologous Stem Cell Transplantation Followed by Polatuzumab Vedotin (PV) Immunoconjugate Therapy in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2024-08-15
Product
Polatuzumab vedotin
Clinical trial
Efficacy and Safety of Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma：a Single-center, Open-label, Pragmatic Clinical Trial
Status: Recruiting, Estimated PCD: 2023-10-13
Product
BTK inhibitor+ Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Clinical trial
A Phase II Study of Acalabrutinib in Ibrutinib-Intolerant Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
Pilot/Feasibility Study of CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Following Autologous Hematopoietic Stem Cell Transplantation for Patients With Intermediate or High Grade B-Lineage Non-Hodgkin Lymphoma (B-NHL)
Status: Recruiting, Estimated PCD: 2028-03-30
Product
Anti-CD19-CAR CMV-specific T-lymphocytes
Product
Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
Clinical trial
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies: A Phase 1 Double Blinded Randomized Placebo Toxicity Trial
Status: Terminated, Estimated PCD: 2022-06-20
Product
Idelalisib
Clinical trial
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2014-12-02
Product
AT7519M
Clinical trial
Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).
Status: Terminated, Estimated PCD: 2020-01-31
Clinical trial
A Phase 2 Study of ABT-199 in Combination With Ibrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma (AIM Study)
Status: Active (not recruiting), Estimated PCD: 2020-11-20
Product
ABT-199
Clinical trial
Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Anti-Thymocyte Globulin
Product
Cytokine-treated Veto Cells
Clinical trial
Zanubrutinib for Maintenance Therapy in Patients With Mantle Cell Lymphoma Who Have Remission After First-line Immunochemotherapy- a Multicenter, Prospective, Phase II Study
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase I/II Study of Syk Inhibitor Entospletinib (GS-9973) in Combination With Obinutuzumab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-Cell Malignancies
Status: Completed, Estimated PCD: 2021-04-29
Product
Entospletinib
Product
Fludarabine-based chemotherapy + CAR-T-CD19 Cells
Clinical trial
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status: Active (not recruiting), Estimated PCD: 2020-06-23
Product
Granulocyte Colony-Stimulating Factor
Clinical trial
A Phase II Study of BTK Inhibitor Acalabrutinib and PI3Kδ Inhibitor Umbralisib in Combination With Ublituximab (AU2) in Patients With Previously Untreated Mantle Cell Lymphoma (MCL)
Status: Active (not recruiting), Estimated PCD: 2022-07-31
Product
Busulfan
Product
MGTA 456
Clinical trial
A Multicenter Phase 2 Study of Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Status: Not yet recruiting, Estimated PCD: 2028-03-31
Clinical trial
An Open-label, Single-arm, Phase 2 Trial of GlOfitamab anD pIrtobrutinib (LOXo-305) in Patients With Mantle Cell Lymphoma and Prior Exposure to a BTK Inhibitor
Status: Recruiting, Estimated PCD: 2032-04-01
Drug
Tocilizumab
Clinical trial
A Phase 1 Study of Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-03-29
Product
Magrolimab
Clinical trial
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-11
Clinical trial
Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age
Status: Active (not recruiting), Estimated PCD: 2022-10-20
Clinical trial
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients </= 70 Years Old With Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Lymphocytes Transduced by RV-SFG.CD19.CD28.4-1BBzeta Retroviral Vector - a Unicenter Phase I/II Clinical Trial
Status: Recruiting, Estimated PCD: 2024-01-01
Product
CD19.CAR T Cells
Clinical trial
Post-Transplant Use of Irradiated Haplo-Allogeneic Cells
Status: Terminated, Estimated PCD: 2022-06-30
Product
Irradiated Allogeneic Cells
Clinical trial
Phase I/II Study of VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Relapsed Indolent Non-Hodgkin's Lymphoma, Transformed or Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2014-11-01
Product
BEAM
Clinical trial
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Status: Completed, Estimated PCD: 2023-09-12
Product
Ofatumumab
Clinical trial
Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-09-15
Clinical trial
Long-term Follow-up and/or Continued Thalidomide (THALOMID®) Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
Status: Completed, Estimated PCD: 2023-08-02
Product
Thalidomide
Clinical trial
A Phase II Study of Acalabrutinib Plus Rituximab in Previously Untreated Elderly Patients With Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2026-08-30
Clinical trial
A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study
Status: , Estimated PCD: 2026-12-31
Clinical trial
A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy With Zanubrutinib as Upfront Treatment in Older Patients With Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2038-08-31
Clinical trial
A Randomized Phase II Trial Evaluating Ibrutinib Plus CD20 Ab and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-03-31
Clinical trial
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
A Phase II Study of Oral Clofarabine in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2013-12-01
Product
Clofarabine
Clinical trial
Phase I Study of LV20.19 CAR T-cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Product
LV20.19 CAR T cells
Clinical trial
A Phase 2 Trial to Evaluate the Efficacy of Bortezomib, Cytarabine, and Dexamethasone in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2021-03-31
Clinical trial
Pilot Study of Glofitamab and Lenalidomide in Patients With Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With a BTK Inhibitor
Status: Recruiting, Estimated PCD: 2028-01-08
Drug
Vitamin D3
Clinical trial
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Pilot Study of Idiotype Vaccine and EPOCH-Rituximab Chemotherapy in Untreated Mantle Cell Lymphoma
Status: Completed, Estimated PCD: 2021-06-09
Product
EPOCH-R
Drug
sargramostim
Product
Idiotype vaccine
Drug
mycophenolate mofetil
Product
Mycophenolate Sodium
Product
Treosulfan
Clinical trial
A Phase Ib/II Study Evaluating the Clinical Activity of Glofitamab Plus Ibrutinib (GLIB) With Obinutuzumab Pretreatment in Previously Untreated Mantle Cell Lymphoma in Patients ≥ 65 or Ages 18-64 With High-Risk Features
Status: Not yet recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination With Ibrutinib in Patients With Select B-Cell Malignancies
Status: Completed, Estimated PCD: 2018-05-01
Product
TGR-1202
Clinical trial
A Randomized Phase II Trial Comparing Rituximab/Bendamustine(RB) Alternating With Rituximab/Bendamustine/Cytarabine(RBAC) With RB as Induction Therapy in Elderly Patients With Newly Diagnosed and Transplant-ineligible Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2029-12-31
Product
RB/RBAC
Product
RB
Clinical trial
A Phase I/II Study of MLN9708 as Post-Transplant Maintenance for Patients With Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplant in First Remission
Status: Active (not recruiting), Estimated PCD: 2023-08-15
Clinical trial
A Phase 2, Multicenter, Single-arm Study of Zanubrutinib (BGB-3111) in Patients With Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment With Ibrutinib and/or Acalabrutinib
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 1/2 Study of Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2028-05-01
Clinical trial
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2025-03-01
Drug
Epcoritamab
Product
Total Body Irradiation
Clinical trial
A Multiple-center Phase 2 Study of Acalabrutinib-Lenalidomide-Rituximab in Patients With Previous Untreated Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
A Phase 1b Study to Assess the Safety and Efficacy of YY-20394 in Subjects With Recurrent and/or Refractory B-cell Hematologic Malignancies
Status: Completed, Estimated PCD: 2021-09-30
Product
YY-20394
Clinical trial
An Open-label, Multi-center, Single-arm Study to Evaluate the Efficacy and Safety of Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL Patients
Status: Not yet recruiting, Estimated PCD: 2028-12-01
Drug
Sonrotoclax
Drug
CD20
Clinical trial
Early Treatment Intensification in Patients With High Risk Mantle Cell Lymphoma Using CAR-T-cell Treatment After an Abbreviated Induction Therapy With Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) as Compared to Standard of Care Induction and Maintenance (Arm B)
Status: Recruiting, Estimated PCD: 2031-06-15
Product
KTE-X19
Clinical trial
Phase I Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-06-24
Clinical trial
An Open-Label Phase 2 Trial of Acalabrutinib Plus Obinutuzumab in Patients With Untreated, Low Tumor Burden Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
Status: Recruiting, Estimated PCD: 2025-01-15